Efficacy of oral treatment with tacrolimus in the renal transplant model in cynomolgus monkeys

Journal of Pharmacological Sciences

Volumn 108, Issue 4, 2008, Pages 529-534

  Kinugasa, Fumitaka ^a   Nagatomi, Itsuo ^a   Ishikawa, Hirofumi ^a   Nakanishi, Tomonori ^a   Maeda, Masashi ^a   Hirose, Jun ^a   Fukahori, Hidehiko ^a   Ooshima, Shinsuke ^a   Noto, Takahisa ^a   Higashi, Yasuyuki ^a   Seki, Nobuo ^a   Mutoh, Seitaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

Cynomolgus monkey; Monkey renal transplant model; Subtherapeutic dose; Tacrolimus; Therapeutic dose

Indexed keywords

DRUG VEHICLE; TACROLIMUS;

ACUTE GRAFT REJECTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; DRUG EFFICACY; DRUG MECHANISM; GRAFT SURVIVAL; HISTOPATHOLOGY; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MALE; MONKEY; MONONUCLEAR CELL; NONHUMAN;

EID: 58149166911     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.08142FP     Document Type: Article

References (21)

1. Scott LJ, McKeage K, Keam SJ, Plosker GL. Tacrolimus: a further update of its use in the management of organ. Drugs. 2003;63:1247-1297.
2. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R, Jain A. FK 506 for liver, kidney, and pancreas transplantation. Lancet. 1989;2:1000-1004.
3. Parikh CR, McSweeney PA. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:2563-2565.
4. Inamura N, Nakahara K, Kino T, Goto T, Aoki H, Yamaguchi I, et al. Prolongation of skin allograft survival in rats by a novel immunosuppressive agent, FK506. Transplantation. 1988;45: 206-209.
5. Murase N, Todo S, Lee PH, Lai HS, Chapman F, Nalesnik MA, et al. Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc. 1987;19:71-75.
6. Todo S, Ueda Y, Demetris JA, Imventarza O, Nalesnik M, Venkataramanan R, et al. Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery. 1988;104:239-249.
7. Todo S, Podesta L, ChapChap P, Kahn D, Pan CE, Ueda Y, et al. Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc. 1987;19:64-67.
8. Collier DS, Thiru S, Calne R. Kidney transplantation in the dog receiving FK-506. Transplant Proc. 1987;19(5 Suppl 6):62.
9. Ochiai T, Nagata M, Nakajima K, Suzuki T, Sakamoto K, Enomoto K, et al. Studies of the effects of FK506 on renal allografting in the beagle dog. Transplantation. 1987;44:729-733.
10. Qi S, Xu D, Peng J, Vu MD, Wu J, Bekersky I, et al. Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. Transplantation. 2000;69:1275-1283.
11. Woodle ES, Thistlethwaite JR, Gordon JH, Laskow D, Deierhoi MH, Burdick J, et al. A multicenter trial of FK506 (tacrolimus) therapy in refractory acute renal allograft rejection. A report of the Tacrolimus Kidney Transplantation Rescue Study Group. Transplantation. 1996;62:594-599.
12. Qi S, Zhu S, Xu D, Wang X, Ouyang J, Jiang W, et al. Significant prolongation of renal allograft survival by delayed combination therapy of FK778 with tacrolimus in nonhuman primates. Transplantation. 2003;75:1124-1128.
13. Chen H, Peng J, Luo H, Loubeau M, Wan X, Xu D, et al. Compromised kidney graft rejection response in Vervet monkeys after withdrawal of immunosuppressants tacrolimus and sirolimus. Transplantation. 2000;69:1555-1561.
14. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney Int. 1999;55:713-723.
15. Fechner JH, Haustein SV, Knechtle SJ. Immunosuppression in nonhuman primates. Transplant Rev. 2006;20:131.
16. Borie DC, Changelian PS, Larson MJ, Si MS, Paniagua R, Higgins JP, et al. Immunosuppression by the JAK3 inhibitor CP-690,550 delays rejection and significantly prolongs kidney allograft survival in nonhuman primates. Transplantation. 2005;79:791-801.
17. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N, Strobertm E, et al. Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am J Transplant. 2005;5:443-453.
18. McDiarmid SV, Colonna JO, Shaked A, Ament ME, Busuttil RW. A comparison of renal function in cyclosporine- and FK-506-treated patients after primary orthotopic liver transplantation. Transplantation. 1993;56:847-853.
19. Su Q, Weber L, Le Hir M, Zenke G, Ryffel B. Nephrotoxicity of cyclosporin A and FK506: inhibition of calcineurin phosphatase. Ren Physiol Biochem. 1995;18:128-139.
20. Wijnen RM, Ericzon BG, Tiebosch AT, Buurman WA, Groth CG, Kootstra G. Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. Transpl Int. 1992;5 Suppl 1:S454-S458.
21. Takeuchi H, Okuyama K, Konno O, Jojima Y, Akashi I, Nakamura Y, et al. Optimal dose and target trough level in cyclosporine and tacrolimus conversion in renal transplantation as evaluated by lymphocyte drug sensitivity and pharmacokinetic parameters. Transplant Proc. 2005;37:1745-1747.